Retired from the corporate world since 1995, Nick Arvanitidis is an active investor in startups, financial markets and real estate. Among his latest seed-investment activities, he is the Founding investor and non-Executive Chairman of Delpor Inc. and Glocu Inc. Delpor develops the next generation Drug Delivery Systems which improve the clinical and commercial value of new and existing drugs and biopharmaceuticals. Glocu is a location-centric social platform, enabling users to socially connect, share their experiences and interact with places on the world map.
Nick was the Founder and CEO of Sequus Pharmaceuticals (1981-1995), a drug delivery company with a focus on treatments for cancer and systemic infections. Among the company’s greatest achievements was the development of Doxorubicin liposome injection (DOXIL). DOXIL is now approved worldwide for the treatment of ovarian and breast carcinoma. The company had an IPO in 1987, was acquired by AlZA Corp. in 1998 and AlZA was acquired by J & J in 1999. Prior to Sequus, Nick served as the Founder and CEO of INTASA Inc. (1968-1983), a management consulting company focused on infrastructural/natural resource planning, growth management and public policy.
He holds a BS in Electrical Engineering from Seattle University, a MS in Electrical Engineering and a Ph.D. in Management Science and Engineering from Stanford University.
Areas of interest: business and finance strategy, team building, leadership and management.